

1 **Universal PCR for Bacteria, Mycobacteria, and Fungi:**
2 **A 10-year Retrospective Review of Clinical Indications and Patient Outcomes**

3 Jeffrey Kubiak MD, PhD;^a Alexandra Morgan;^a Andrea Kirmaier, PhD;^a

4 Ramy Arnaout MD, DPhil;^{ab#†} Stefan Riedel MD, PhD^{a#†}

5 ^aDepartment of Pathology, Beth Israel Deaconess Medical Center, Department of Pathology, Boston, MA
6 02215; ^bDivision of Clinical Informatics, Department of Medicine, Beth Israel Deaconess Medical Center,
7 Boston, MA 02215; [†]Co-corresponding authors

8 #To whom correspondence should be addressed at:

9 Stefan Riedel	Ramy Arnaout
10 Department of Pathology	Department of Pathology
11 BIDMC	BIDMC
12 330 Brookline Avenue	330 Brookline Avenue
13 Boston, MA 02215	Boston, MA 02215
14 sriedel@bidmc.harvard.edu	rarnaout@bidmc.harvard.edu

15 **Running Title:** Clinical indications and outcomes of universal PCR

16 **Keywords:** universal PCR, molecular diagnostics, laboratory utilization, outcomes

17 **Abstract**

18 Universal PCR for bacteria, mycobacteria, and fungi can aid in the diagnosis of occult infections,
19 especially in the case of fastidious organisms or when prior antimicrobial treatment compromises
20 culture growth. However, the limitations of this technology, including lack of specificity, high cost, long
21 turnaround time, and lack of susceptibility data, may limit its effect on clinical outcomes. We performed
22 a retrospective analysis of all specimens sent for universal PCR over a 10-year period from 2013-2022,
23 focusing on clinical indications for test utilization and patient outcomes. A total of 708 specimens were
24 sent from 638 patients. Of those specimens, 163 were positive, for an overall positivity rate of 23%. Pre-
25 analytic factors associated with a positive universal PCR result were the presence of organisms on Gram
26 stain or histology, the presence of neutrophils on Gram stain, and growth on culture. Positivity rates
27 varied significantly by specimen type. 20% of all organisms detected were deemed contaminants by the
28 clinical services. A positive universal PCR led to a change in antibiotic management in 29% of cases.
29 Positive fungal universal PCR results sent from hospitalized patients were associated with worse
30 outcomes, including increased hospital mortality. Our findings suggest that factors such as the presence
31 of organisms or neutrophils on Gram stain, specimen source/clinical context, and anticipated changes in
32 management based on results should be strongly considered when making stewardship decisions
33 regarding the appropriateness of this testing modality.

34

35 Introduction

36 Universal PCR for bacteria, mycobacteria, and fungi is an attractive technology for the diagnosis of occult
37 infections that may not be detectable by routine microbiology laboratory methods¹. As molecular
38 diagnostics such as these continue to evolve, laboratory stewardship is becoming increasingly important
39 to ensure that these novel technologies are being utilized to maximize benefit to the patient while
40 minimizing unnecessary healthcare costs.

41 Universal PCR is best utilized in cases of culture-negative infections, especially in cases of fastidious
42 organisms or when antimicrobials were given prior to specimen collection that compromise culture
43 growth². While universal PCR has a fairly low sensitivity as a standalone assay³, prospective studies have
44 shown that when used in conjunction with culture, the overall detection rate may be enhanced over the
45 use of culture alone⁴⁻⁷. Various studies have supported the use of universal PCR in cases of
46 meningitis^{5,8,9}, endophthalmitis^{10,11}, joint and bone infections^{6,12-15}, pleural effusions^{16,17}, fungal
47 sinusitis,¹⁸ and endocarditis¹⁹⁻²². While positive universal PCR results have been reported to lead to
48 changes in antimicrobial treatment, there is considerable variability between studies regarding the
49 extent to which these results impact antimicrobial management²³⁻²⁵.

50 Universal PCR is not without its limitations. Due to its non-specific nature, there is a high rate of false-
51 positive results from contamination, especially in non-sterile body sites²⁶. Universal PCR also cannot
52 provide antimicrobial susceptibility data, and even in the case of a positive result clinicians must rely on
53 epidemiologic data to guide coverage. In the absence of in-house universal PCR testing capacity, sending
54 specimens to reference laboratories can take a week or longer to return results to the ordering
55 institution, leaving clinicians to rely on empiric coverage of suspected organisms during a critical time in
56 hospitalized patients' care. Lastly, this assay comes at a high cost compared to other routine
57 microbiology testing methods, typically hundreds of dollars²⁷. Some studies have suggested that the

58 combination of the lack of susceptibility data, the high rate of contamination, the sensitivity and faster
59 turnaround time of concurrently submitted routine microbiology assays, and the cost mean that
60 universal PCR provides little to no value to patient management or prognosis²⁸⁻³⁰.

61 In this context, we aimed to further address the clinical utility of universal PCR, focusing on patterns of
62 utilization and patient outcomes. We performed a retrospective review of all universal PCR tests sent
63 from our hospital network over a 10-year period and determined the impact of positive universal PCR
64 results on patient antimicrobial management and hospitalized patient outcomes. These data may impart
65 diagnostic and prognostic significance for clinicians to determine the merit of testing for their patients
66 and can ultimately guide stewardship decisions about the use of this technology for challenging
67 diagnostic cases.

68

69 **Methods**

70 We performed a retrospective chart review for all patients for whom universal PCR testing was ordered
71 from our 743-bed tertiary-care medical center. These orders were placed by both outpatient and
72 inpatient clinical teams, typically in conjunction with the infectious disease consult service. Clinicians
73 had the option to order any combination of bacterial, mycobacterial, or fungal universal PCR based on
74 their clinical judgement of potential etiologies of the patient's infection. All universal PCR orders
75 required review and approval by a clinical director of our institution's microbiology laboratories. The
76 specimens were sent to the University of Washington Molecular Diagnosis Microbiology Section
77 (Seattle, WA). Their test relies on sequencing of the 16S rRNA gene, the 65-kD heat shock protein, or the
78 28S rRNA gene plus internal transcribed spacer regions to broadly detect and speciate bacterial,
79 mycobacterial, and fungal DNA sequences, respectively. In the case of bacterial and fungal universal

80 PCR, reflex testing to next-generation sequencing was included in cases where multiple templates were
81 present.

82 We queried our institution's clinical data repository to retrieve information on all specimens ordered for
83 universal PCR from our electronic medical record network over the 10-year period from January 2013
84 through November 2022. A chart review was performed on all patients to determine patient factors and
85 outcomes, including demographic data, relevant clinical laboratory data including concurrent Gram stain
86 results and culture results, specimen type, clinical indications, antibiotic treatment decisions, inpatient
87 status, and hospitalization outcomes. We considered other laboratory tests to be concurrent with the
88 specimen sent for universal PCR if either the same specimen was utilized for both assays or if both
89 specimens were retrieved from the same location during the same surgical procedure. We relied on
90 clinical judgement by physicians treating the patient to determine if a detected organism was
91 considered clinically relevant or a presumed contaminant.

92 All analyses were performed using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) and
93 RStudio 1.1.463 (Posit, Boston, MA). Population proportion confidence intervals were calculated to
94 determine 95% confidence intervals for PCR positivity rates for different populations. A chi-squared test,
95 odds ratio, or unpaired Student's T-test was used for comparisons. P values were then corrected for
96 multiple comparisons using the Benjamini-Hochberg method and a corrected p value of <0.05 was
97 considered to be statistically significant. The Beth Israel Deaconess Medical Center Institutional Review
98 Board reviewed the study protocol and determined it to be exempt (protocol no. 2017D000478).

99

100 **Results**

101 Over the 10-year period from January 2013 to November 2022, a total of 708 specimens from 638
102 patients were sent to our reference laboratory for universal PCR. Of those, 574 were tested for bacteria,

103 321 for mycobacteria, and 294 for fungi. Universal PCR specimens had an average turnaround time of 12
104 days from order to result. The overall positivity rate was 23% (163/708, 95% CI 20-26%). The positivity
105 rate for those tested for bacteria was 19% (109/574, 95% CI 16-22%), for mycobacteria was 6% (18/321,
106 95% CI 3.1-8.1%), and for fungi was 14% (40/294, 95% CI 9.7-18%) (**Figure 1A**).

107 We examined whether other laboratory tests performed on specimens sent for universal PCR were
108 associated with a positive PCR result (**Table 1**), including Gram stain results and results of concurrent
109 histopathology slides examined in surgical pathology. The presence of organisms on Gram stain (23/44
110 positive, 52% [95% CI 38-67%]) was associated with positive universal PCR results ($p < 0.05$) and the
111 absence of neutrophils on Gram stain (29/207 positive, 14% [95% CI 9-19%]) was negatively associated
112 with positive universal PCR results ($p < 0.05$). We observed no significant difference in positivity rate
113 between paraffin-embedded blocks and fresh frozen tissue. However, the presence of organisms seen
114 on histology slides (34/73 positive, 47% [95% CI 35-58%]) was also significantly associated with a positive
115 universal PCR result ($p < 0.05$). The presence of granulomata on histology was not associated with a
116 positive PCR result.

117 Specimens sent for universal PCR had concurrent cultures taken in 656 cases (93%), with 154/656 (23%)
118 of those cultures positive for an organism. Having a culture positive for any organism was significantly
119 associated with positive universal PCR results (53/154 positive, 34% [95% CI 27-42%], $p < 0.05$). Of those
120 cases with a positive culture and positive universal PCR result, there was concordance between those
121 results for organism identification in 36/53 (68%) of cases.

122 A variety of specimen types were sent for universal PCR analysis. These included: artery,
123 bronchoalveolar lavage, bone, brain (including dura and meninges), breast, cerebrospinal fluid, digits,
124 intervertebral disc, epidural tissue, foreign bodies, joints, liver, lung, lymph node, pericardium,
125 peritoneum, pleura, skin, soft tissue/muscle, heart valves, vitreous, esophagus, fallopian tube, bowel,

126 bone marrow, uterus, and myocardium. Joint and bone tissue specimens were most frequent, with 165
127 and 148 specimens sent, respectively. Specimen types varied considerably in the overall positivity rates
128 (**Figure 1B, Supplemental Table 1**). The highest positivity rates were seen in bronchoalveolar lavage
129 specimens (5/8, 63% [95% CI 29%-96%]) and heart valves (11/19, 58% [95% CI 36%-80%]), and the
130 lowest positivity rate was seen with pericardial specimens (0/9, 0%).

131 Likewise, clinical indications for testing varied considerably. The clinical indications for testing included:
132 osteomyelitis, septic arthritis, abscess, granulomata seen on surgical pathology, mass/lesion,
133 endocarditis, pneumonia, cellulitis, lymphadenopathy, pericardial or pleural effusion, arteritis,
134 meningitis, peritonitis, sinusitis, aplastic anemia, endophthalmitis, or a non-healing surgical wound. The
135 highest positivity rate was noted for endocarditis (11/23 positive, 48%, [95% CI 27-68%]). A complete
136 table of positivity rates for specimen sources broken down by clinical indication and pathogen type can
137 be found in **Supplemental Table 1**.

138 76% of all patients with positive universal PCR results were on empiric antimicrobial therapy prior to
139 receiving results of the assay. Following the reporting of universal PCR results to the online medical
140 record, clinicians considered the universal PCR result to be a contaminating organism in 33/163 (20%,
141 95% CI 14-26%) cases (**Figure 2A**). When broken down by specimen type, bronchoalveolar lavage (BAL)
142 specimens were considered to have the highest contamination rate, with 4/5 (80%, 95% CI 45-100%)
143 positive PCRs considered to be the result of a contaminant (**Figure 2B**). 48/163 (29%, 95% CI 22-36%)
144 positive results led to a change in antimicrobial management. Positive results led to a change in
145 antibiotic management in 5/5 cases (100%) of intervertebral discs and 8/11 (72%, 95% CI 46-98%) of
146 heart valves, while certain specimen types such as liver, brain, and BAL did not have any results lead to a
147 change in patient management. Reasons that antimicrobial management was not changed include the
148 patient already being on appropriate empiric therapy (68/163, 42% [95% CI 34%-50%]), the patient
149 improving without antibiotic intervention (8/163, 5% [95% CI 2-8%]), awaiting mycobacterial

150 susceptibility results from a concurrently submitted culture (2/163, 2% [95% CI 0-4%]), or patient
151 discharge to hospice or death prior to return of the results (4/163, 3% [95% CI 1-5%]).

152 Finally, we determined whether a positive universal PCR result was associated with particular
153 hospitalization outcomes. Of the 708 total specimens, 593 were from inpatients and 115 were from
154 outpatients, with 136/593 (23%, 95% CI 16-31%) and 27/115 (23%, 95% CI 20-26%) being positive,
155 respectively. From the time of specimen collection, universal PCR results from inpatients took an
156 average of 12 days to return, and 76% (95% CI 72%-79%) of the results returned after the patient was
157 discharged from the hospital. Among inpatients who were tested via universal PCR, 13/593 (2%, 95% CI
158 1-4%) died, 204/593 (34%, 95% CI 31-38%) required discharge to extended care facilities, including
159 rehabilitation services and hospice care, and 123/593 (21%, 95% CI 17-24%) were readmitted to the
160 hospital within 30 days of discharge. Universal PCR results returning prior to hospital discharge did not
161 significantly affect hospitalization outcomes such as mortality and discharge to rehab services compared
162 to patients whose results did not return until after discharge.

163 A positive universal PCR for fungi was significantly associated with increased hospital mortality (OR 7.65
164 [95% CI 1.80 – 32.4], $p < 0.05$) (**Figure 3**). A positive fungal PCR result was not significantly associated
165 with discharge to rehabilitation or hospice care facilities (OR 2.38 [95% CI 1.10-5.18, $p = 0.052$]) or
166 readmission within 30 days following hospital discharge (OR 2.09 [95% CI 0.93-4.76], $p = 0.07$). There
167 were no significant differences in hospital mortality, discharge to rehabilitation or hospice facilities, or
168 hospital readmission within 30 days among inpatients with positive bacterial or mycobacterial results.
169 There were no significant differences in hospitalization length of stay associated with positive results for
170 bacteria, mycobacteria, or fungi (**Supplemental Figure 1**).

171

172 **Discussion**

173 In this study, we examined clinical factors associated with positive universal PCR results, as well as
174 associated hospitalization outcomes. In line with prior literature, we found that positive Gram stain
175 results or histology results, neutrophils on Gram stain, and growth in culture were all significantly
176 associated with positive universal PCR results^{25,31}.

177 Our clinicians ordered universal PCR on a wide variety of specimen types, most frequently in the case of
178 orthopedic infections. We found that although they were the most frequently ordered, orthopedic
179 specimens such as joint, bone, and intervertebral discs were among the least likely specimens to return
180 positive. While less frequently ordered, heart valves were among the highest positivity rates and most
181 frequently led to changes in antibiotic management. These findings are in line with current literature
182 demonstrating great utility of universal PCR for endocarditis, so much so that some studies have even
183 suggested that universal PCR be incorporated as part of the modified Duke's criteria for diagnosis of
184 infective endocarditis²².

185 In our cohort, 20% of all positive universal PCR results were considered contaminants by clinical teams.
186 We relied on clinical judgement about whether a positive universal PCR result represented a true
187 infection or contamination. We believe that the fraction of results considered "contaminated" was
188 actually underestimated in our data set due to clinicians potentially over-treating clinically insignificant
189 organisms detected on universal PCR out of an abundance of caution (Note, PCR disagreed with culture-
190 based identification in 32% of cases). With a lack of gold standard in determining whether a resulting
191 organism is truly causative of infection, universal PCR will likely continue to produce organism
192 identifications that will present a clinical dilemma over whether to treat.

193 Among patients with positive universal PCR results, only 29% of results led to a change in antibiotic
194 management. The impact of positive universal PCR results on antibiotic management varies widely in
195 the literature, with studies showing a change in management in 5% to 76% of cases^{16,24,25,32}. The majority

196 of our patients were on empiric treatment prior to universal PCR results, and so clinicians must consider
197 the value that universal PCR brings to potentially changing or narrowing treatment, and how strongly
198 that will impact their patients' care. A limitation of this study is that we were unable to perform a similar
199 analysis to determine the changes in antibiotic management that may have resulted from a negative
200 universal PCR result. While positive universal PCR results were invariably acknowledged in clinician
201 notes, negative results were less frequently documented and therefore could not be directly correlated
202 with treatment decisions. This may be a fruitful topic for future work.

203 We found that positive results from universal PCR for fungi were associated with worse hospital
204 outcomes. 4/30 (13%) positive cases in hospitalized inpatients were associated with patient death, and
205 15/30 (50%) cases required discharge to extended care facilities or hospice. This finding likely reflects
206 that patients with occult fungal infections are likely to be sicker with more severe systemic illness
207 compared to patients without infections as the etiology of their disease.

208 There were no circumstances in which a positive result of universal PCR led to demonstrable
209 improvements in hospitalization outcomes. Patients with positive universal PCR results for bacteria and
210 mycobacteria did not have any change in hospital mortality, discharge to extended care facilities,
211 readmission within 30 days, or length of stay. However, our universal PCR results took an average of 12
212 days from specimen collection to result, and 76% of hospitalized patients were discharged before results
213 returned. When considering the utility of this assay, turnaround time is a critical component. With
214 improvements in turnaround time through the development of commercialized assays, it is possible that
215 earlier time to appropriate antimicrobial intervention may be able to improve hospitalization
216 outcomes^{9,13}. However, many of these patients were treated empirically with broad-range antibiotics
217 prior to results and it can be difficult to parse out specific improvements that occurred as a result of
218 potentially narrowing coverage. It can be challenging to quantify other metrics of improper antibiotic
219 use such as medication side effects, excess healthcare cost, and the promotion of resistance based on a

220 retrospective analysis. With that said, universal PCR data may also prove valuable to infection control for
221 epidemiologic studies; for example, in our hospital network, a cluster of four cases of *Acinetobacter junii*
222 detected in orthopedic specimens in 2022 prompted an internal infection control investigation to
223 identify potential sources of OR contamination to reduce false positive rates.

224 Further studies focused on other outcomes as outlined above are needed to fully assess the utility of
225 universal PCR for the diagnosis of occult infections. With little changes in hospitalization outcomes
226 occurring as a result of universal PCR, clinicians should carefully consider the desired outcomes of a
227 universal PCR weighed against the potential high cost of testing and the risk of over-treating organisms
228 which may not truly be causative of infection. Given the significant variation in ordering and treatment
229 practices among physicians, there will continue to be fluctuations in positivity rates and changes in
230 antimicrobial practice from institution to institution until standardized guidelines are established for the
231 use of this technology, highlighting the need for intensive studies into the utility of universal PCR in
232 clinical practice.

233

234 **Acknowledgements**

235 We thank the University of Washington Molecular Diagnosis Microbiology Section (Seattle, WA), our
236 reference laboratory to whom we sent all samples to perform universal PCR studies. We also thank our
237 clinical and laboratory staff for specimen submission and processing.

238

239 **Conflicts of Interest**

240 The authors have no conflicts of interest to disclose.

241

242 **Author Contributions**

243 J.K. and S.R. conceived the studies and established parameters for data collection. A.M. and R.A.
244 retrieved the data from our institution's clinical data repository. Data analysis was performed by J.K. and
245 A.K. Manuscript was written by J.K, R.A, and S.R. All authors reviewed the manuscript, data, and
246 approved the final version.

247

248 **References**

- 249 1. Church DL, Cerutti L, Gürtler A, Griener T, Zelazny A, Emler S. Performance and Application of
250 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology
251 Laboratory. *Clin Microbiol Rev.* 2020;33(4):e00053-19. doi:10.1128/CMR.00053-19
- 252 2. Sontakke S, Cadenas MB, Maggi RG, Diniz PPVP, Breitschwerdt EB. Use of broad range 16S rDNA
253 PCR in clinical microbiology. *Journal of Microbiological Methods.* 2009;76(3):217-225.
254 doi:10.1016/j.mimet.2008.11.002
- 255 3. Morel AS, Dubourg G, Prudent E, et al. Complementarity between targeted real-time specific
256 PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven diagnosis of infectious
257 diseases. *Eur J Clin Microbiol Infect Dis.* 2015;34(3):561-570. doi:10.1007/s10096-014-2263-z
- 258 4. Rampini SK, Bloemberg GV, Keller PM, et al. Broad-Range 16S rRNA Gene Polymerase Chain
259 Reaction for Diagnosis of Culture-Negative Bacterial Infections. *Clinical Infectious Diseases.*
260 2011;53(12):1245-1251. doi:10.1093/cid/cir692
- 261 5. Schuurman T, de Boer RF, Kooistra-Smid AMD, van Zwet AA. Prospective Study of Use of PCR
262 Amplification and Sequencing of 16S Ribosomal DNA from Cerebrospinal Fluid for Diagnosis of

- 263 Bacterial Meningitis in a Clinical Setting. *J Clin Microbiol.* 2004;42(2):734-740.
264 doi:10.1128/JCM.42.2.734-740.2004
- 265 6. Tkadlec J, Peckova M, Sramkova L, et al. The use of broad-range bacterial PCR in the diagnosis of
266 infectious diseases: a prospective cohort study. *Clinical Microbiology and Infection.* 2019;25(6):747-
267 752. doi:10.1016/j.cmi.2018.10.001
- 268 7. Lass-Flörl C, Mutschlechner W, Aigner M, et al. Utility of PCR in Diagnosis of Invasive Fungal
269 Infections: Real-Life Data from a Multicenter Study. *J Clin Microbiol.* 2013;51(3):863-868.
270 doi:10.1128/JCM.02965-12
- 271 8. Deutch S, Pedersen LN, Pødenphant L, et al. Broad-range real time PCR and DNA sequencing for
272 the diagnosis of bacterial meningitis. *Scandinavian Journal of Infectious Diseases.* 2006;38(1):27-35.
273 doi:10.1080/00365540500372861
- 274 9. Welinder-Olsson C, Dotevall L, Hogevik H, et al. Comparison of broad-range bacterial PCR and
275 culture of cerebrospinal fluid for diagnosis of community-acquired bacterial meningitis. *Clinical*
276 *Microbiology and Infection.* 2007;13(9):879-886. doi:10.1111/j.1469-0691.2007.01756.x
- 277 10. Mishra D, Satpathy G, Chawla R, Venkatesh P, Ahmed NH, Panda SK. Utility of broad-range 16S
278 rRNA PCR assay versus conventional methods for laboratory diagnosis of bacterial endophthalmitis in
279 a tertiary care hospital. *Br J Ophthalmol.* 2019;103(1):152-156. doi:10.1136/bjophthalmol-2018-
280 312877
- 281 11. Ogawa M, Sugita S, Watanabe K, Shimizu N, Mochizuki M. Novel diagnosis of fungal
282 endophthalmitis by broad-range real-time PCR detection of fungal 28S ribosomal DNA. *Graefes Arch*
283 *Clin Exp Ophthalmol.* 2012;250(12):1877-1883. doi:10.1007/s00417-012-2015-7


- 284 12. Fenollar F, Roux V, Stein A, Drancourt M, Raoult D. Analysis of 525 Samples To Determine the
285 Usefulness of PCR Amplification and Sequencing of the 16S rRNA Gene for Diagnosis of Bone and
286 Joint Infections. *J Clin Microbiol.* 2006;44(3):1018-1028. doi:10.1128/JCM.44.3.1018-1028.2006
- 287 13. Kühn C, Disqué C, Mühl H, Orszag P, Stiesch M, Haverich A. Evaluation of Commercial Universal
288 rRNA Gene PCR plus Sequencing Tests for Identification of Bacteria and Fungi Associated with
289 Infectious Endocarditis. *J Clin Microbiol.* 2011;49(8):2919-2923. doi:10.1128/JCM.00830-11
- 290 14. Gille J, Wallstabe S, Schulz AP, Paech A, Gerlach U. Is non-union of tibial shaft fractures due to
291 nonculturable bacterial pathogens? A clinical investigation using PCR and culture techniques. *J Orthop*
292 *Surg Res.* 2012;7(1):20. doi:10.1186/1749-799X-7-20
- 293 15. Qu X, Zhai Z, Li H, et al. PCR-Based Diagnosis of Prosthetic Joint Infection. *J Clin Microbiol.*
294 2013;51(8):2742-2746. doi:10.1128/JCM.00657-13
- 295 16. Lampejo T, Ciesielczuk H, Lambourne J. Clinical utility of 16S rRNA PCR in pleural infection.
296 *Journal of Medical Microbiology.* 2021;70(5). doi:10.1099/jmm.0.001366
- 297 17. Insa R, Marín M, Martín A, et al. Systematic Use of Universal 16S rRNA Gene Polymerase Chain
298 Reaction (PCR) and Sequencing for Processing Pleural Effusions Improves Conventional Culture
299 Techniques. *Medicine.* 2012;91(2):103-110. doi:10.1097/MD.0b013e31824dfdb0
- 300 18. Lieberman JA, Bryan A, Mays JA, et al. High Clinical Impact of Broad-Range Fungal PCR in
301 Suspected Fungal Sinusitis. Hanson KE, ed. *J Clin Microbiol.* 2021;59(11):e00955-21.
302 doi:10.1128/JCM.00955-21

- 303 19. Faraji R, Behjati-Ardakani M, Moshtaghioun SM, et al. The diagnosis of microorganism involved
304 in infective endocarditis (IE) by polymerase chain reaction (PCR) and real-time PCR: A systematic
305 review. *The Kaohsiung J of Med Scie*. 2018;34(2):71-78. doi:10.1016/j.kjms.2017.09.011
- 306 20. Harris KA, Yam T, Jalili S, et al. Service evaluation to establish the sensitivity, specificity and
307 additional value of broad-range 16S rDNA PCR for the diagnosis of infective endocarditis from
308 resected endocardial material in patients from eight UK and Ireland hospitals. *Eur J Clin Microbiol*
309 *Infect Dis*. 2014;33(11):2061-2066. doi:10.1007/s10096-014-2145-4
- 310 21. Armstrong C, Kuhn TC, Dufner M, et al. The diagnostic benefit of 16S rDNA PCR examination of
311 infective endocarditis heart valves: a cohort study of 146 surgical cases confirmed by histopathology.
312 *Clin Res Cardiol*. 2021;110(3):332-342. doi:10.1007/s00392-020-01678-x
- 313 22. Marín M, Muñoz P, Sánchez M, et al. Molecular Diagnosis of Infective Endocarditis by Real-Time
314 Broad-Range Polymerase Chain Reaction (PCR) and Sequencing Directly From Heart Valve Tissue.
315 *Medicine*. 2007;86(4):195-202. doi:10.1097/MD.0b013e31811f44ec
- 316 23. Kerkhoff AD, Rutishauser RL, Miller S, Babik JM. Clinical Utility of Universal Broad-Range
317 Polymerase Chain Reaction Amplicon Sequencing for Pathogen Identification: A Retrospective Cohort
318 Study. *Clinical Infectious Diseases*. 2020;71(6):1554-1557. doi:10.1093/cid/ciz1245
- 319 24. Marbjerg LH, Holzknecht BJ, Dargis R, Dessau RB, Nielsen XC, Christensen JJ. Commercial
320 bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from
321 normally sterile sites: diagnostic value and implications for antimicrobial treatment. *Diagnostic*
322 *Microbiology and Infectious Disease*. 2020;97(2):115028. doi:10.1016/j.diagmicrobio.2020.115028

- 323 25. Naureckas Li C, Nakamura MM. Utility of Broad-Range PCR Sequencing for Infectious Diseases
324 Clinical Decision Making: a Pediatric Center Experience. McElvania E, ed. *J Clin Microbiol.*
325 2022;60(5):e02437-21. doi:10.1128/jcm.02437-21
- 326 26. Renvoisé A, Brossier F, Sougakoff W, Jarlier V, Aubry A. Broad-range PCR: Past, present, or future
327 of bacteriology? *Médecine et Maladies Infectieuses*. 2013;43(8):322-330.
328 doi:10.1016/j.medmal.2013.06.003
- 329 27. Aggarwal D, Kanitkar T, Narouz M, Azadian BS, Moore LSP, Mughal N. Clinical utility and cost-
330 effectiveness of bacterial 16S rRNA and targeted PCR based diagnostic testing in a UK microbiology
331 laboratory network. *Sci Rep*. 2020;10(1):7965. doi:10.1038/s41598-020-64739-1
- 332 28. Stempak LM, Vogel SA, Richter SS, Wyllie R, Procop GW. Routine Broad-Range Fungal
333 Polymerase Chain Reaction With DNA Sequencing in Patients With Suspected Mycoses Does Not Add
334 Value and Is Not Cost-Effective. *Archives of Pathology & Laboratory Medicine*. 2019;143(5):634-638.
335 doi:10.5858/arpa.2017-0299-OA
- 336 29. Miller K, Harrington SM, Procop GW. Acid-fast Smear and Histopathology Results Provide
337 Guidance for the Appropriate Use of Broad-Range Polymerase Chain Reaction and Sequencing for
338 Mycobacteria. *Archives of Pathology & Laboratory Medicine*. 2015;139(8):1020-1023.
339 doi:10.5858/arpa.2013-0705-OA
- 340 30. Panousis K, Grigoris P, Butcher I, Rana B, Reilly JH, Hamblen DL. Poor predictive value of broad-
341 range PCR for the detection of arthroplasty infection in 92 cases. *Acta Orthopaedica*. 2005;76(3):341-
342 346. doi:10.1080/00016470510030805



- 343 31. Basein, Tinzar, Gardiner, Bradley, Andujar-Vazquez, Gabriela, et al. Clinical Utility of Universal
344 PCR and its Real-world Impact on Patient Management. In: *IDSA Stewardship: Impact of Diagnostics*.
345 Vol 4. ; 2017:S627.
- 346 32. Racsa LD, DeLeon-Carnes M, Hiskey M, Guarner J. Identification of bacterial pathogens from
347 formalin-fixed, paraffin-embedded tissues by using 16S sequencing: retrospective correlation of
348 results to clinicians' responses. *Human Pathology*. 2017;59:132-138.
349 doi:10.1016/j.humpath.2016.09.015
- 350
- 351

352




353

354 **Figure 1.** Total number of specimens sent for universal PCR and positivity rate by pathogen type (A) and
355 by specimen source (B). A single specimen could be sent for more than one universal PCR at a time.
356 Error bars represent the 95% population proportion confidence intervals for positive results.



358 **Figure 2.** Management decisions made by the clinical team based on positive universal PCR results by
359 pathogen type (A) and by specimen source (B). Error bars represent the 95% population proportion
360 confidence intervals for positive results. Antimicrobial course was not changed in the case of death,
361 transition to comfort care, patient improvement without intervention, satisfactory empiric treatment, or
362 presumed contamination of universal PCR sample.



363

364 **Figure 3.** Hospitalization outcomes following positive universal PCR results compared to specimens
365 which were negative via universal PCR. Error bars represent the 95% confidence interval around the
366 odds ratio.

367 **Table 1.** Pre-analytic determinants of positive universal PCR results.

	Total specimens	Total positives by universal PCR	Percent positive (95% CIs)	Corrected p value
Total	708	163	23% (20-26%)	---
Female Gender	342	73	21% (17-26%)	0.81
Age > 50	498	113	23% (19-26%)	0.97
Hardware Present	160	35	22% (15-28%)	0.97
Gram stain organisms present	44	23	52% (38-67%)	0.0001
Neutrophils absent on gram stain	178	29	16% (11-22%)	0.021
Cultures positive	154	53	34% (27-42%)	0.016
Organisms seen on histology	73	34	47% (35-58%)	0.0001
Granuloma on histology	72	12	17% (8-25%)	0.42
Formalin fixed tissue	68	22	32% (21-43%)	0.20
Outpatient	115	27	23% (16-31%)	0.97
Inpatient	593	136	23% (20-26%)	0.97

368